Accepted for Publication: September 9, 2022.
Published: October 28, 2022. doi:10.1001/jamanetworkopen.2022.38961
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Hammons LR et al. JAMA Network Open.
Corresponding Author: Meera Mohan, MD, MS, Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 (email@example.com).
Author Contributions: Drs Hammons and Mohan had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Dhakal, Chhabra, D’Souza, Mohan.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Szabo, Dhakal, D’Souza, Mohan.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Hammons, Szabo.
Administrative, technical, or material support: Janardan.
Supervision: Dhakal, Mohan.
Conflict of Interest Disclosures: Dr Dhakal reported consulting for Janssen Pharmaceuticals and Karyopharm Therapeutics Inc and serving on the advisory boards of Sanofi, Amgen Inc, Natera, and Arcellx, Inc, outside the submitted work. Dr D’Souza reported serving on clinical trial advisory boards for Janssen Pharmaceuticals and Prothena Corporation PLC, performing clinical trials for Teneobio, Inc, Regeneron Pharmaceuticals, Inc, and Caelum, and serving on the advisory boards of Bristol-Myers Squibb Company, Caelum, and Pfizer Inc outside the submitted work. Dr Mohan reported receiving institutional research funding from Takeda Pharmaceutical Company Limited, Novartis AG, Celgene/Bristol-Myers Squibb Company, and GSK PLC outside the submitted work. No other disclosures were reported.
Disclaimer: All information and materials in the manuscript are original.
Meeting Presentation: These findings were presented in part at the Annual Meeting of the American Society of Clinical Oncology; June 4, 2022; Chicago, Illinois.
SZ , Garfall
AL , van de Donk
et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet
. 2021;398(10301):665-674. doi:10.1016/S0140-6736(21)01338-6